The Termeer Foundation Announces Recipients of 2021 Henri Termeer Fellowship

The Termeer Foundation (www.termeerfoundation.org), a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines, today announced that the Class of 2021 Henri Termeer Fellowships have been named; the latest to receive this honor within the Fellowship program which began in 2018.

The Henri Termeer Fellowship is awarded annually to those emerging leaders within the life science industry who have shown initial promise as company founders, CEOs or heads of life science organizations and are dedicated to developing life-changing treatments for patients. Fellows receive membership in The Henri Termeer Network, a select group of emerging and established healthcare leaders who provide access to their collective and valuable industry experience to help all Termeer Fellows advance their businesses and scientific programs. Additional Fellowship benefits include quarterly mentor presentations, monthly peer-to-peer learning presentations, individual 1:1 mentoring, and access to other events and initiatives sponsored by The Termeer Foundation.

"This year's group of Termeer Fellows represents the best of what the life science industry has to offer in its future leaders, as they are extraordinary young men and women who inspire us with their talents and deep commitment to patients," said Belinda Termeer, President of The Termeer Foundation. "Each Fellow brings a unique perspective to their company, and collectively have the potential to make a deep impact in patients' lives and continue to influence the life science industry with future developments."

The 2021 Fellows include: Jenna Baker, CEO, Gypsy Basin Genomics, Inc.; Jacob Becraft, CEO, Strand Therapeutics; Martin Bruncko, CEO, Camarque Bioscience; Nick Davis, CEO, Theon Therapeutics; Amy Ripka, CEO, Lucy Therapeutics; and Rachel Salzman, CEO, UltraSquared Bio. This year's Class are focused in the following therapeutics areas: RNA therapeutics, rare genetic neuromuscular disorders, genomic testing for HPV cancers, mitochondrial therapeutics, immunotherapy, and ultra-rare disease gene therapy. Information about the 2021 Class of Termeer Fellows can be found here.

"When we established the Termeer Fellows program in 2018, it was the Foundation's goal to identify and celebrate the future leaders of science and medicine," said Alan Walts, Co-Founder and Member of the Board of Directors, The Termeer Foundation. "Henri Termeer wrote the book on supporting the next-generation of biotechnology trailblazers and we wanted to be true to his legacy. The Class of 2021, much like the previous classes, represents the innovation, entrepreneurship and vision necessary for establishing companies that have the potential to transform the life science industry."

About The Termeer Foundation

Building on the bold legacy of Henri Termeer, who pioneered groundbreaking treatments for rare diseases, The Termeer Foundation connects life science innovators and catalyzes the creation of new medicines. The Foundation's network of emerging and established healthcare innovators cultivates tomorrow's leaders and leverages their collective expertise to solve complex problems in drug development and accessibility. The Foundation also integrates its network with academic institutions, nonprofits, regulatory agencies and other organizations across the global healthcare ecosystem to provide expert counsel, stimulate innovation, eliminate barriers to progress, and ultimately connect the world of healthcare until every patient has a cure. Visit us at www.termeerfoundation.org or on LinkedIn @TermeerFoundation.